2026-01-27 - Analysis Report
**Company Overview**
Regeneron Pharmaceuticals is a biotechnology company that develops and commercializes medicines for the treatment of serious diseases.

**Return Rate Analysis**
| Ticker | Cumulative Return |
| --- | --- |
| REGN | 52.07% |
| VOO | 127.58% |

The divergence between REGN and VOO is -75.51% on the last day of the data. This indicates that the comparative return rate of REGN is lower than VOO.

**Alpha and Beta Analysis**
| Periode |   CAGR |   MDD |  Alpha | Beta |  Cap(B) |
|--------|--------|-------|--------|-------|---------|
| 2016-2018 | -3.00% | 24.10% | -12.00% |      39.6B |
| 2017-2019 |  9.00% | 27.30% | -16.00% |      39.8B |
| 2018-2020 |  31.00% | 27.30% |   7.00% |      51.2B |
| 2019-2021 |  40.00% | 27.30% | -25.00% |      66.9B |
| 2020-2022 |  72.00% | 25.70% |  68.00% |      76.5B |
| 2021-2023 |  61.00% | 24.40% |  43.00% |      93.1B |
| 2022-2024 |  -1.00% | 40.50% | -30.00% |      75.5B |
| 2023-2025 | -17.00% | 57.20% | -92.00% |      81.8B |

**Moving Average Analysis**
| Timeframe | Close | 5-day SMA | 20-day SMA | 60-day SMA |
|----------|-------|-----------|------------|-------------|
|        - | $762.65 | $750.96 | $767.40 | $734.08     |

**Indicator Analysis**
| Metric   | Value |
|----------|-------|
| MRI      | 0.70  |
| RSI      | 49.82 |
| PPO      | -0.51 |
| E.R. (%) | 0.80  |
| Change   | Sharp rebound (-1.21%) |

The relative divergence change is +2.10 and 7-day Rank change is +18, both showing an improving trend.

**News & Events**
1. Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026 - Quiver Quantitative
2. REGN or ILMN: Which Is the Better Value Stock Right Now? - Yahoo Finance
3. Regeneron Pharmaceuticals (REGN) Valuation Check After Eylea HD Approval And Ongoing Dupixent Momentum - simplywall.st
4. A big Wall Street flip just changed the Regeneron narrative - thestreet.com
5. Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
6. Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat

**Analyst Opinions**
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.69 (~Buy)
- Opinions: 26
- Target Price (avg/high/low): $831.19 / $1057.00 / $630.00

**Quarterly Earnings Analysis**
| Date       | EPS | Revenue |
|------------|-----|---------|
| 2025-10-28 | 14.09 | 3.75 B$ |
| 2025-08-01 | 13.24 | 3.68 B$ |
| 2025-04-29 | 7.58  | 3.03 B$ |
| 2024-10-31 | 12.4  | 3.72 B$ |

**Financial Information**

* Revenue and Profitability:
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.75B | 86.11% |
| 2025-06-30 | $3.68B | 85.58% |
| 2025-03-31 | $3.03B | 84.67% |
| 2024-12-31 | $3.79B | 85.08% |
| 2024-09-30 | $3.72B | 86.80% |

* Capital and Profitability:
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $30.96B | 4.72% |
| 2025-06-30 | $29.94B | 4.65% |
| 2025-03-31 | $29.39B | 2.75% |
| 2024-12-31 | $29.35B | 3.13% |
| 2024-09-30 | $29.33B | 4.57% |

Overall Analysis:
Regeneron Pharmaceuticals reported strong sales and profitability in Q4 2025, driven by Dupixent and Eylea HD. Analysts are optimistic, with a buy opinion (mean of 1.69) and a target price of $831.19. The company's financial health is robust, with a profit margin of 86.11% and ROE of 4.72%.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.